{"nctId":"NCT00560885","briefTitle":"AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation","startDateStruct":{"date":"2007-11"},"conditions":["Atrial Fibrillation"],"count":55,"armGroups":[{"label":"AtriCure Bipolar System","type":"EXPERIMENTAL","interventionNames":["Device: AtriCure Bipolar System"]}],"interventions":[{"name":"AtriCure Bipolar System","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject is greater than or equal to 18 years of age\n2. Subject has history of permanent atrial fibrillation as defined by the ACC/AHA/ESC Guidelines\n3. Subject is scheduled to undergo elective on-pump cardiac surgical procedure(s) for one or more of the following:\n\n   * Mitral valve repair or replacement\n   * Aortic valve repair or replacement\n   * Tricuspid valve repair or replacement\n   * Coronary Artery Bypass procedures\n   * Atrial Septal Defect Repair\n   * Patent Foramen Ovale closure\n4. Subject's Left Ventricular Ejection Fraction â‰¥ 30%\n5. Subject is able and willing to provide written informed consent and comply with study requirements\n6. Subject has life expectancy of at least 1 year\n\nExclusion Criteria:\n\n1. Stand alone AF without indication(s) for concomitant CABG, valve surgery, ASD repair, or PFO closure\n2. Previous cardiac ablation including catheter ablation, AV-nodal ablation, or surgical Maze procedure\n3. Wolff-Parkinson-White syndrome\n4. Prior cardiac surgery (Redo)\n5. Class IV NYHA heart failure symptoms\n6. Prior history of cerebrovascular accidents within 6 months or at any time if there is residual neurological deficit\n7. Documented MI within 6 weeks prior to study enrollment\n8. Need for emergent cardiac surgery (i.e. cardiogenic shock)\n9. Known carotid artery stenosis greater than 80%\n10. LA size greater than or equal to 8cm\n11. Current diagnosis of active systemic infection\n12. Severe peripheral arterial occlusive disease defined as claudication with minimal exertion\n13. Pregnancy or desire to get pregnant within 12-months of the study enrollment\n14. Preoperative need for an intra-aortic balloon pump or intravenous inotropes\n15. Renal failure requiring dialysis or hepatic failure\n16. Requires anti-arrhythmic drug therapy for the treatment of a ventricular arrhythmia\n17. Therapy resulting in compromised tissue integrity including: thoracic radiation, chemotherapy, long term treatment with oral or injected steroids, or known connective tissue disorders","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null}]}]}]},{"type":"PRIMARY","title":"Composite Acute Major Adverse Event Rate, Within 30 Days Post-procedure or Hospital Discharge","description":"Major Adverse Events consist of Death within 30 days or beyond 30 days if considered device related, Excessive Bleeding, Stroke, TIA or MI. A clinic visist was performed at 30 days to fully assess the patient for adverse events.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Patients Free From AF, Independent of Antiarrhythmic Drug Status as Determined by Holter Monitoring at 6 Months.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite 6-month Post-procedure Major Adverse Event Rate.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":55},"commonTop":["Anaemia","Pleural effusion","Bradycardia","Haemorrhage","Cardiac Failure Congestive"]}}}